Skip to main content

Risk Adapted Treatment of Myelofibrosis: A Focus on Quality-of-Life (Regionals)


Click here to complete your registration.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.


I. Welcome and Introduction
II. Personalized Treatment Selection for Myelofibrosis
III. Improving Patient Quality-of-Life
IV. Q&A Session and Activity Roundup

Myelofibrosis is a rare myeloproliferative neoplasm associated with poor outcomes. Because early stages of disease are associated with minimal symptoms, most patients are diagnosed with advanced disease. In these patients, overall survival can be short and the risk of transformation to leukemia is high. To improve patient outcomes, it is important that high-risk patients with advanced disease are identified early and receive appropriate treatment. While historically there have been limited treatment options for advanced myelofibrosis, several novel JAK inhibitors have been approved in the past decade that significantly improve disease symptoms and overall survival, improving patient quality of life. However, use of these agents can be challenging, both in determining the optimal treatment selection, identifying when to switch therapies, and minimizing the impact of disease symptoms and treatment-related adverse events on patient quality-of-life.

This activity, Risk Adapted Treatment of Myelofibrosis: A Focus on Quality-of-Life, will provide hematologists and oncologists with important information on the role of risk stratification in guiding treatment selection, efficacy and safety data for current and emerging myelofibrosis therapies, and strategies for integrating these agents into clinical practice in a way that prolongs survival, minimizes adverse events, and improves patient quality-of-life.


John Mascarenhas, MD
Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Tisch Cancer Institute, Division of Hematology/Oncology
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

Ruben A. Mesa, MD FACP
Executive Director
Mays Family Foundation Distinguished University Presidential Chair
Professor of Medicine
Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, TX


The intended audience for this educational initiative includes hematologists and oncologists, the clinicians responsible for the diagnosis and treatment of patients with myelofibrosis.

At the conclusion of this activity, participants should be able to:

  • Use guideline recommended scoring systems to develop risk-informed treatment plans for patients with myelofibrosis
  • Integrate the latest clinical trial evidence into the selection and sequencing of treatments for patients with advanced myelofibrosis
  • Develop strategies to improve patient quality of life by minimizing disease symptoms and treatment-related toxicities
  • Communicate with patients regarding their disease, symptoms, and treatment options

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email

ABIM MOC RECOGNITION STATEMENT Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of the activity is vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships will be mitigated by PCME.

Disclosure and mitigation information will be made known to the participants prior to the start of the activity.

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

To ensure your computer is compatible for the live event, please perform a system check by clicking on the link or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.

  • 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
  • Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
  • 512 MB of RAM (1 GB recommended)
  • Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
  • 1.83 GHz Intel Core Duo or faster processor
  • 512 MB RAM (1 GB recommended)
  • Mac OS X 10.12, 10.13 and 10.14
  • Mozilla Firefox, Apple Safari, Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
  • The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
  • Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
  • Google Android 4.4 or later
  • Apple iOS: iOS 8.1.2 or later

DSL/cable (wired connection recommended)

There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test, with a score of 70% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

This program is supported by an educational grant from Bristol Myers Squibb.

PCME Privacy Policy